Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Cellectar Biosciences INC NEW (CLRB)

Pharmaceutical Preparations

https://www.cellectar.com

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

100 CAMPUS DRIVE
FLORHAM PARK, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/19/2005

Market Cap

71,339,311

Shares Outstanding

12,290,000

Weighted SO

12,288,325

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

DFFN --.--%

DFFN --.--%

MNPR --.--%

PULM --.--%

TENX --.--%

BPTH --.--%

CBIO --.--%

Beta

0.9870

Last Div

0.0000

Range

1.6-4.45

Chg

-0.0400

Avg Vol

616995

Mkt Cap

71339311

Exch

NASDAQ

Country

US

Phone

608 441 8120

DCF Diff

1.2526

DCF

0.7374

Div Yield

0.0000

P/S

215.9402

EV Multiple

-0.7574

P/FV

2.2319

Div Yield %

0.0000

P/E

-1.1455

PEG

-0.0494

Payout

0.0000

Current Ratio

2.5429

Quick Ratio

2.5429

Cash Ratio

2.4607

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

10098.4922

CCC

-10098.4922

Gross Margin

0.1911

Op Margin

-127.9091

Pretax Margin

-154.5070

Net Margin

-154.3254

Eff Tax Rate

0.0027

ROA

-1.1882

ROE

-18.5560

ROCE

-1.5862

NI/EBT

0.9988

EBT/EBIT

1.2079

EBIT/Rev

-127.9091

Debt Ratio

0.0128

D/E

0.0210

LT Debt/Cap

0.0178

Total Debt/Cap

0.0205

Int Coverage

-340.6875

CF/Debt

-70.3117

Equity Multi

1.6398

Rec Turnover

0.0000

Pay Turnover

0.0361

Inv Turnover

0.0000

FA Turnover

0.2187

Asset Turnover

0.0077

OCF/Share

-1.3138

FCF/Share

-1.3440

Cash/Share

1.3641

OCF/Sales

-116.7037

FCF/OCF

1.0230

CF Coverage

-70.3117

ST Coverage

-521.0550

CapEx Coverage

-43.5319

Div&CapEx Cov

-43.5319

P/BV

2.2319

P/B

2.2319

P/S

215.9402

P/E

-1.1455

P/FCF

-1.8088

P/OCF

-1.5147

P/CF

-1.5147

PEG

-0.0494

P/S

215.9402

EV Multiple

-0.7574

P/FV

2.2319

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 01, 21:00 Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q GlobeNewswire Inc. Aug 23, 21:00 Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq GlobeNewswire Inc. Jan 22, 06:40 Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient GlobeNewswire Inc. Jan 16, 06:40 Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data GlobeNewswire Inc. Jan 12, 06:44 Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results GlobeNewswire Inc. Jan 11, 06:40 Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting GlobeNewswire Inc. Jan 08, 06:30 Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia GlobeNewswire Inc. Dec 19, 08:30 Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation GlobeNewswire Inc. Dec 12, 08:30 Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform

Revenue Product Segmentation